The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

Press Release

Global Campaign for Microbicides Lauds Milestone in HIV Prevention Findings That Daily Use of Anti-Retroviral Protects Against HIV Infection

Results From Global iPrEx Trial Offer Hope for Those at Highest Risk of Infection

November 23, 2010

Johannesburg, South Africa and Washington, D.C. -- The Global Campaign for Microbicides (GCM) welcomes today's news from the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Disease (NIAID) of the US National Institutes of Health (NIH) and the Gladstone Institutes of the University of California, San Francisco that daily use of oral emtricitabine (FTC) with tenofovir (TDF) in one tablet shows promise to safely and effectively help to prevent HIV infection among men who have sex with men (MSM).

The iPrEx Study, conducted in six countries spanning four continents, found an average of 43.8 percent fewer HIV infections among individuals at high risk for infection who took a FTC/TDF tablet compared to those given a placebo tablet. FTC/TDF is already being used to treat people living with HIV infection.

"This has been a landmark year for HIV prevention research," said Yasmin Halima, director of the Global Campaign for Microbicides. "We now have proof of concept that both topical gels and oral pills have potential to work in preventing HIV among those at highest risk."

The Phase III study, which was conducted among 2,499 HIV -- negative gay men, male to female transgendered women and other MSM at 11 sites in Brazil, Ecuador, Peru, South Africa, Thailand, and the United States, demonstrates that Pre Exposure Prophylaxis (PrEP), such as FTC/TDF, is likely to be a useful addition to combination approaches, including safer sex counseling and condom use, to prevent HIV in MSM. The study also offers significant insights into human behaviour, risk perceptions and the importance of adherence, all of which will be valuable for existing and future trials.

While the trial did not study the effectiveness of FTC/TDF in women, it gives the Global Campaign and scientific community reason to be optimistic about its potential. Women around the world continue to bear the greatest burden of HIV and findings from other PrEP trials that are currently underway, such as VOICE, will be an important milestone in demonstrating success and the move toward licensure of both the gel and oral pills for women who are most at risk.

Given the Global Campaign's mission to ensure access to new and existing HIV prevention options, especially for women, 2013 -- the year that results of the VOICE trial are due -- may prove to be an even more exciting year. The Global Campaign has been advocating for and supporting the critical need for more HIV prevention methods for nearly 12 years.

"There is light at the end of the long HIV prevention research tunnel," continued Halima. "With good news on the product front, efforts must be stepped up to ensure that the drug is approved and political and community will is established for such products to get in the hands of people who need them as quickly as possible."

More From This Resource Center

Undetectable Viral Load and HIV Prevention: What Do Gay and Bi Men Need to Know?

Do HIV-Negative Gay Men Need Condoms if They're on PrEP? Here's What I Tell My Patients

This article was provided by Global Campaign for Microbicides. Visit the Global Campaign for Microbicides' website to find out more about their activities, publications and services.
See Also
More on HIV Medications
More Research on Truvada (Tenofovir/FTC)

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.